ACRV_OUT_1 [2025-04-15 15:38:26 -0400] 4476 Bytes | 1235 tokens | Cum: 1235 tkns (15.44% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Acrivon Therapeutics (ACRV) which is at 2.0350 up from 1.5000. So, I pulled together a bunch of data for you to look over real fast. It's still early, 3:38:24 PM on Tue Apr 15, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Acrivon Therapeutics (ACRV)
IPO: 2022-11-15 (2 Years Ago)
Market Cap: $55,805,634
Shares Outstanding: 31,350,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Here’s a list of headlines for Acrivon Therapeutics:

Apr-14-25 09:35AM - Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)
Apr-07-25 04:05PM - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Mar-28-25 12:00PM - Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know
Mar-28-25 12:00PM 09:35AM - Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks
Mar-27-25 05:44PM - Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
Mar-19-25 08:00AM - Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Feb-06-25 08:16AM - Acrivon Therapeutics announces FDA granted BDD for ACR-368
Feb-06-25 08:16AM 04:54AM - FDA grants breakthrough designation for Acrivons endometrial cancer assay

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-09-14T07:10:00Z - Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
B2 - 2024-07-10T13:01:37Z - Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research
B3 - 2024-07-05T13:31:22Z - AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC - Zacks Investment Research
B4 - 2024-07-02T16:12:00Z - SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
B5 - 2024-07-02T15:00:00Z - AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
B6 - 2024-06-27T14:26:00Z - Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Acrivon Therapeutics (ACRV).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ACRV_OUT_3 [2025-04-15 15:38:26 -0400] 1168 Bytes | 321 tokens | Cum: 1558 tkns (19.48% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/09/14/2946234/0/en/Acrivon-Therapeutics-Reports-Positive-Endometrial-Cancer-Data-from-Ongoing-ACR-368-Registrational-Intent-Phase-2-Study-at-ESMO-Advancement-of-ACR-2316-into-Clinic-Ahead-of-Timeline.htmlAcrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_5 [2025-04-15 15:38:27 -0400] 1007 Bytes | 281 tokens | Cum: 1841 tkns (23.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-07T20:14:08Z - Acrivon appoints new chief medical officer to advance cancer trials By Investing.com...
A2 - 2025-04-07T20:14:08Z - Acrivon appoints new chief medical officer to advance cancer trials By Investing.com...
A3 - 2025-04-07T20:16:51Z - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator M...
A4 - 2025-04-07T20:15:37Z - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator M...
A5 - 2025-04-07T20:13:07Z - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator M...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ACRV_OUT_7 [2025-04-15 15:38:28 -0400] 1181 Bytes | 326 tokens | Cum: 2169 tkns (27.11% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Acrivon appoints new chief medical officer to advance cancer trials By Investing.com**Date: 2025-04-07Source: {'uri': 'za.investing.com', 'dataType': 'news', 'title': 'Investing.com South Africa'}URL: https://za.investing.com/news/company-news/acrivon-appoints-new-chief-medical-officer-to-advance-cancer-trials-93CH-3646033WATERTOWN, Mass. - Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company currently valued at $47.3 million, announced the appointment of Dr. Mansoor Raza Mirza as its new chief medical officer, effective April 9, 2025. Dr. Mirza, a renowned clinician in gynecological oncology, will spearhead the clinical development of Acrivon's pipeline, including the ACR-368 Phase 2b trial in endometrial cancer and the ACR-2316 Phase 1 study in selected solid tumors. According to InvestingPro data, the company maintains a strong liquidity position

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_9 [2025-04-15 15:38:29 -0400] 1181 Bytes | 278 tokens | Cum: 2449 tkns (30.61% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): with a current ratio of 10.55, though it faces challenges with cash burn.

The company's current chief medical officer, Dr. Jean-Marie Cuillerot, will depart on the same day. Dr. Mirza brings a wealth of experience, having led numerous trials to global regulatory approvals and established new standards of care in his field. His recent role as chief oncologist at Copenhagen University National Medical Center and his involvement in the development of national guidelines for cancer management underscore his expertise. This leadership change comes as the stock trades near its 52-week low of $1.40, with InvestingPro analysis suggesting the stock is currently undervalued.

Dr. Mirza's appointment is timely as Acrivon advances its lead candidate, ACR-368, which targets CHK1 and CHK2 and has received Fast Track designation from the FDA. The company is also developing ACR-2316, a WEE1/PKMYT1 inh

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_11 [2025-04-15 15:38:30 -0400] 1181 Bytes | 254 tokens | Cum: 2705 tkns (33.81% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): ibitor, and is utilizing its AP3 platform for drug discovery and development. While the company reported a net loss of $80.56 million in the last twelve months, two analysts have recently revised their earnings estimates upward for the upcoming period, suggesting potential optimism about the company's pipeline progress.

Acrivon's CEO, Dr. Peter Blume-Jensen, expressed enthusiasm for Dr. Mirza's leadership as the company progresses towards potential regulatory submissions and approvals. He also acknowledged Dr. Cuillerot's contributions to the company.

Dr. Mirza's track record includes authoring numerous publications and serving as a principal investigator in clinical trials that led to the approval of therapies like Zejula for ovarian cancer. His appointment is expected to further Acrivon's mission to deliver precision oncology medicines to patients.

The information provided is based

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_13 [2025-04-15 15:38:31 -0400] 1181 Bytes | 287 tokens | Cum: 2994 tkns (37.43% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): on a press release statement from Acrivon Therapeutics.

In other recent news, Acrivon Therapeutics reported operating expenses of $25 million for the fourth quarter of 2024, with an earnings per share (EPS) of ($0.60). The full year's operating expenses totaled $89.2 million, resulting in an EPS of ($2.43). H.C. Wainwright maintained its Buy rating for Acrivon, though it adjusted the price target to $19.00 from $22.00, following the company's strategic decision to shift focus away from ovarian and bladder cancer treatments. Cantor Fitzgerald also reiterated its Overweight rating, noting the strong data on ACR-368 for endometrial cancer despite some efficacy dilution. JMP Securities upheld its Market Outperform rating with a $17.00 price target, highlighting the promising profile of ACR-368 in metastatic endometrial cancer.

The company's recent updates indicate a strategic focus on endo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_15 [2025-04-15 15:38:31 -0400] 743 Bytes | 182 tokens | Cum: 3178 tkns (39.73% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): metrial cancer, with ACR-368 and ACR-2316 being central to its pipeline. Acrivon ended 2024 with $179.5 million in cash and equivalents, which is expected to support operations into 2027. Analysts are closely monitoring Acrivon's progress, particularly regarding the potential for an accelerated approval pathway based on new data. The upcoming R&D event is expected to provide further insights into the company's clinical-stage assets and strategic direction.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_17 [2025-04-15 15:38:33 -0400] 1104 Bytes | 301 tokens | Cum: 3481 tkns (43.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-07 8-K Item 7.01 Regulation FD Disclosure. Appointment of Mansoor Raza Mirza, M.D . as Chf Medical Off

On April 7, 2025, Acrivon Therapeutics, Inc. (the Company) appointed Mansoor Raza Mirza, M.D., to the position of Chf Medical Off, effective as of April 9, 2025 (the Effe...

S5 - 2025-03-27 8-K Item 7.01 Regulation FD Disclosure.

On March 27, 2025, Acrivon Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Curr Repor...

S6 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and related notes and ot...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ACRV_OUT_19 [2025-04-15 15:38:35 -0400] 1129 Bytes | 281 tokens | Cum: 3764 tkns (47.05% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure. Appointment of Mansoor Raza Mirza, M.D . as Chief Medical Officer

On April 7, 2025, Acrivon Therapeutics, Inc. (the Company) appointed Mansoor Raza Mirza, M.D., to the position of Chief Medical Officer, effective as of April 9, 2025 (the Effective Date). A copy of the press release announcing the appointment of Dr. Mirza is attached as Exhibit 99.1 to this report.

The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ACRV_OUT_21 [2025-04-15 15:38:49 -0400] 6752 Bytes | 1850 tokens | Cum: 5616 tkns (70.20% of 8k)
==========================================================================

This is our set of metrics for Acrivon Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 1,251,983 | Perf Month: -64.18% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 130.88K | Perf Quarter: -64.57% | Short Float: 4.08% | ROE: -54.07% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 10.51 | Index: RUT | Short Ratio: 6.78 | ROI: -44.91% |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 35.00 | Market Cap: 61.77M | Short Interest: 0.89M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.41 | Shs Outstand: 31.23M | Beta: 1.94 | EPS Surprise: 9.58% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -26.92% | Shs Float: 21.74M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -55.06% | Inst Own: 66.27% | Sales past 5Y: 0.00% | Earnings: Mar 27 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -70.06% | Insider Own: 30.67% | Employees: 78 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: 44.85% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by Acrivon Therapeutics officers or majority shareholders (if available).

Inside Trans: Acrivon Therapeutics, Inc. (ACRV) by Miller Mary (Chief Legal Officer) on 2025-04-01
- Stock Option (Right to Buy): 15616 shares at $0 (D)

Inside Trans: Acrivon Therapeutics, Inc. (ACRV) by Levy Adam D. (Chief Financial Officer) on 2025-04-01
- Stock Option (Right to Buy): 35209 shares at $0 (D)

No transactions recorded.

Inside Trans: Acrivon Therapeutics, Inc. (ACRV) by Blume-Jensen Peter (President and CEO) on 2025-03-01
- Stock Option (Right to Buy): 390390 shares at $0 (D)
- Stock Option (Right to Buy): 140540 shares at $0 (I)

Inside Trans: Acrivon Therapeutics, Inc. (ACRV) by Cuillerot Jean-Marie (Chief Medical Officer) on 2025-03-01
- Stock Option (Right to Buy): 78078 shares at $0 (D)

Inside Trans: Acrivon Therapeutics, Inc. (ACRV) by Devroe Eric (Chief Operating Officer) on 2025-03-01
- Stock Option (Right to Buy): 140540 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -80556000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.05
Average Volume: 326069.68
30-Day High: 5.61
30-Day Low: 1.36

[Detailed Financials: TTM 2024]
- Total Assets: $196,588,000.0
- Total Liabilities: $19,802,000.0
- Total Equity: $176,786,000.0
- Current Assets: $181,629,000.0
- Current Liabilities: $17,214,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.38

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $3,587,000.0

[Detailed Financials: FY 2024]
- Total Assets: $196,588,000.0
- Total Liabilities: $19,802,000.0
- Total Equity: $176,786,000.0
- Current Assets: $181,629,000.0
- Current Liabilities: $17,214,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.38

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $3,587,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Acrivon Therapeutics (ACRV).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Acrivon Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because ACRV is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ACRV.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ACRV could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ACRV to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Acrivon Therapeutics.

11) ETHICAL_RATING[]
Rate Acrivon Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Acrivon Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ACRV_IN_23 [2025-04-15 15:38:50 -0400] 126 Bytes | 29 tokens | Cum: 5924 tkns (74.05% of 8k)
==========================================================================

====================================
[2025-04-15 15:38:50] # Analysis Completed
Elapsed Time: 25.16 seconds